A study testing whether a GLP-1 medicine, semaglutide, can help people with interstitial lung disease lose weight.

Recruiting now. Registry record last updated April 21, 2026.

Who can join: Adults 18 to 80, have obesity, BMI 30+.
What you take: Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 4 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 1Sponsor University of PennsylvaniaDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 8

What this study is for

Primary condition: Obesity. Also studied in: Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension.

Full scientific study title: Feasibility of Semaglutide in Advanced Lung Disease.

Who can join

Age18 to 80SexAnyBMI30 or higher

Adults 18 to 80, have obesity, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension
Age \> 18
BMI \> 30 kg/m2
Requires supplemental oxygen on exertion
Stable treatment regimen X 90 days

Key exclusion criteria

Diabetes
Pregnant or Breastfeeding
Recent weight loss
Recent or chronic GI complaints
History of gastroparesis

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Pennsylvania1 site

University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
Apurva Rajeapurva.raje@pennmedicine.upenn.edu

Follow this trial

We email you if NCT05746039 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: January 29, 2024. Expected completion: December 28, 2027. Last updated on ClinicalTrials.gov: April 21, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.